

## In Vitro Models to Study Hepatotoxicity

DAVID A. GRONEBERG,<sup>1,2</sup> CHRISTIAN GROSSE-SIESTRUP,<sup>3</sup> AND AXEL FISCHER<sup>1</sup>

<sup>1</sup>*Department of Pediatric Pneumology and Immunology*

<sup>2</sup>*Department of Medicine, and*

<sup>3</sup>*Department of Comparative Medicine and Experimental Animal Sciences, Charité School of Medicine, Humboldt-University Berlin, Germany*

### ABSTRACT

Drug discovery and development consists of a series of processes starting with the demonstration of pharmacological effects in experimental cell and animal models and ending with drug safety and efficacy studies in patients. A main limitation is often the unacceptable level of toxicity with the liver as the primary target organ. Therefore, approaches to study hepatic toxicity in the early phase of drug discovery represent an important step towards rational drug development. A variety of in vitro liver models have been developed in the past years. Next to their use in drug development, they can also be applied to study environmental toxins and their hepatotoxicity. The 3 main approaches are ex vivo isolated and perfused organ models, precision-cut liver slices and cell culture models. Although the advantage of whole organ perfusions is based on the assessment of physiologic parameters such as bile production and morphologic parameters such as tissue histology, cell culture models can be efficiently used to assess cellular metabolism, cytotoxicity and genotoxicity. The advantage of precision-cut liver slices is based on the juxtaposition of cellular assays and tissue morphology. None of these models can be compared as they all focus on different fields of hepatotoxicology. For the future, the ideal setup for testing the hepatic toxicity of a new compound could of primary studies in cell or slice cultures to assess cellular effects and secondary studies using ex vivo perfused organs to examine gross organ function parameters and histology.

*Keywords.* Liver; toxicology; liver slices; cell culture; perfusion.

### INTRODUCTION

The development of new drugs consists of a variety of single steps leading from the discovery of pharmacological effects in cell and animal models to the assessment of toxicity and finally to the demonstration of efficacy and safety in humans (46, 90). Although the process that leads to the discovery of potent pharmacological effects has been reduced by rational drug designing in the past years, a variety of problems may occur in the preclinical and clinical development and lead to the failure of a compound. One of the most prominent factors that limits drug development is based on the compound's toxicity towards human health and therefore, using the field of investigational toxicology, different models have been established to assess this factor in an early stage.

Due to its anatomical position between the gastro-intestinal tract and the systemic circulation and its biochemical properties, the liver plays an important role in the metabolism of exogenous substances. A large amount of both nutrients and noxious substances reach the liver through intestinal uptake and portal vein flow. Next to major hepatic functions such as the uptake, storage, and release of peptides, amino acids, lipids, carbohydrates and vitamins, the liver is the principal organ in biotransformation processes of exogenous

substances. Among them, numerous xenobiotics may have toxic effects. Apart from its role in the detoxication process of xenobiotics the liver may also convert substances into toxic products or be subject to the effects of compounds that are hepatotoxic, such as ethionine or galactosamine (95).

Hepatic drug metabolism occurs in the hepatocytes that represent with 80% of the total volume and 60% of the total cell number the predominant cell type found in the liver (44).

The potential of drug-based or environmental hepatotoxins to generate liver cell injury results from a complex interaction of cellular processes and is based on direct or indirect reactions of the toxins with basic hepatocyte constituents such as proteins, lipids, RNA, or DNA. The most frequent hepatic reaction towards toxic effects is hepatic steatosis but a variety of many other lesions are known (96). In general, the reactions leading to these organ injuries all involve specific sequences that can be analyzed at the molecular, cellular, or organ level. Whereas in vivo studies on hepatotoxicity are limited by animal welfare/ethical concerns and difficulties to distinguish primary and secondary toxic effects, in vitro liver preparations are increasingly used as they offer different approaches on all levels of investigational toxicology.

### *In Vitro Liver Models*

There are 3 different major models to study the hepatotoxic effects: The most frequently used model is the liver cell culture model that can be applied to examine effects of

---

Address correspondence to: David A. Groneberg, Biomedical Research Center, BMFZ Forum 4, Charité Campus Virchow, Augustenburger Platz 1, 13353 Berlin, Germany; e-mail: david.groneberg@charite.de .

TABLE 1.—Advantages and limitations of different in vitro liver models.

Model	Advantages	Limitations
Isolated cells	All species including humans Whole livers or biopsies as source Information on cellular toxicity Cryopreservation Several compounds at different concentrations	No bile measurement No cell-to-cell interaction No preserved anatomy
Liver slices	Lobular structure partly preserved All species including humans Whole livers or biopsies as source Information on cellular toxicity Several compounds at different concentrations	No bile measurement No cell-to-cell interaction No preserved anatomy
Isolated organs	Closest to in vivo conditions Anatomy preserved Bile flow preserved Hemodynamic parameters can be assessed	Short-term viability (2–4 h) Only a few compounds can be assessed with one organ No studies on human liver High number of animals used Complexity of the setup

drugs/toxins on isolated hepatocytes on the cellular level. In contrast, isolated perfused organs display an approach towards the assessment of organ physiology and morphology and represent the closest model to the in vivo situation. As a bridge between these two approaches, precision-cut liver slices can be used to examine cellular aspects of liver toxicology in a tissue-specific background.

Each of these approaches has a number of advantages and disadvantages and therefore based on the specific toxicological question, a model selection should be performed when investigating drug- or environmental substances-induced hepatic toxicity (Table 1).

#### *Isolated Liver Cell Models*

To date, cultured liver cells represent the most frequently used in vitro liver cell model. These models usually consist of isolated hepatocytes and have been established as valid in vitro toxicological models for many years (4). Next to rat and other rodent hepatocytes, even human-cultured hepatocytes have been established as models to study hepatic drug metabolism and genotoxic potential of substances (20, 21, 53). Also, the characteristics of human hepatocytes were compared to other rodent and primate models (14, 38, 100).

The methodology of liver cell cultures has been improved over the last years and currently, a variety of isolation, culture, and cryopreservation models have been established and evaluated (99). Shortly after the first description of hepatocyte isolation by collagenase- and hyaluronidase-dissociation (61, 62), new improvements were made by perfusing the livers in situ with the dissociating agents (12). Later, the protocol of the 2-step collagenase technique for rat hepatocytes has been established (84, 85), which was later modified (98) and works well for short-term cultures of hepatocytes of a variety of species including rat, monkey, pig, dog, rabbit, and human. For long-term models, a variety of approaches including addition of basement membrane (83, 88), culture in a collagen sandwich (32, 65), or coculture with epithelial cells (78) has been proposed.

To guarantee the survival of hepatocytes isolated from individual donors, cryopreservation or cold storage techniques can be applied that lead to an indefinite (23, 29) or 48-hour (54, 77) extension, respectively. However, the viability of

stored cells is much lower than that of freshly isolated hepatocytes and dependent on factors such as initial cell integrity, ice crystal formation, and hypoxia during freezing and toxicity of cryopreservation substances.

In contrast to other liver cell types such as immortalized hepatoma cell lines, hepatocytes have the capacity for biotransformation, which is crucial for toxicological studies. However, they lose activity of specific systems such as cytochrome P450 if compared to in vivo levels. Therefore specific strategies using the addition of matrix materials or agents have been developed to maintain metabolizing activity (8, 9, 87). Studies addressing the metabolizing capacity of human, rat, dog, and monkey cultured hepatocytes revealed that for the model drug adinazolam, 24 hours after isolation the cells still generated metabolites similar to those formed in vivo; therefore, it was concluded that for at the least the first few days, cultured hepatocytes may be used to identify potential toxic metabolites (99).

Cultured hepatocytes have been used as applications in investigative toxicology for a variety of questions so far. In this respect, to investigate the mechanisms of hepatic toxicity, a combination of cell functional and cytotoxicity assay displays a useful approach. For cytotoxicity assays, propidium iodide uptake or lactate dehydrogenase (LDH) release and for functional assays, levels of cytochrome P450 (13, 53) or structural alterations (27) may be measured on a cellular level. Based on these methodological aspects, a variety of studies used cultured hepatocytes to study liver toxicology (6, 7, 28, 93, 100, 101, 105).

A significant disadvantage of hepatocyte cultures is the absence of organ-specific cell-to-cell interactions. In this respect, liver hepatocytes show a marked heterogeneity along the porto-central axis regarding enzyme activity or subcellular architecture resulting in phenotypes that alter within different zones of the liver lobuli. This zonation also affects drug-metabolizing enzymes such as some cytochrome P450 isoenzymes, NADPH-cytochrome c reductase or UDP-glucuronyl transferase enzymes (44, 45). Although only a few drug-metabolizing enzymes have been reported in other hepatic cell types such as endothelial, Kupffer, biliary epithelial cells or fibroblasts (66–68, 76, 82), their direct or indirect role in drug-induced hepatotoxicity is well documented (33, 36, 60, 73).

#### *Isolated Perfused Organs*

In contrast to isolated hepatocyte models, the isolated perfused liver represents the closest in vitro model of the in vivo situation. Since the first use of isolated perfused livers for physiologic research (47) and for treatment of patients with hepatic coma or prior to transplantation (2, 3, 22, 34), a large number of studies have focused on the establishment of valid isolated organ models. Contrary to kidney perfusion models that were first established using a variety of small animal models such as the rat (42) or rabbit (79), the first liver perfusion setups were primarily based both on porcine organs (31) and small animal organs (1, 56). The major advantages of the isolated perfused livers are the preservation of the 3-dimensional organ structure with all its cell-to-cell interactions and the possibility of real-time bile collection and analysis. Furthermore, this model allows the study of

hemodynamic parameters if blood is used as a perfusate (24–26, 72).

So far, the rat model of isolated perfused liver has been used in a variety of studies for the investigation of drug- and chemical-induced hepatotoxicity. A variety of substances have been examined including aliphatic alcohols (91), thioacetamide (71), acetaminophen (17), methacrylate (11), cyclosporine (30), insecticides such as lindane or mirex (94, 104), phalloidin (16), solvents such as dimethylacetamide (74), metals such as mercury, cadmium, copper, vanadium, or aluminium (18, 92, 106), aromatic amines (5, 57), muscle relaxants such as atracurium (19), or antibiotic agents such as nitrofurantoin (86).

However, as small laboratory animal organ models such as the rat model have significant differences in organ size, function, and geometry compared to the human liver, isolated perfused porcine, canine or bovine livers display a better approach to simulate human *in vivo* conditions. A variety of different porcine liver perfusion models have been described so far (2, 31, 37, 55, 64). In all these studies, the proper assessment of liver viability is essential and it is generally agreed that the levels of oxygen consumption and bile acid production are reliable parameters.

Asanguineous perfusates were used in the majority of studies (2, 58, 59, 64) and only in a few studies, autologous blood was used (10, 63, 81). In contrast to blood-free perfusion setups, these studies allowed to assess hepatic parameters under physiological perfusion conditions with autologous blood. The blood pressure can be kept within physiological ranges in both hepatic artery and portal vein as compared to human parameters. In contrast, the continuously increasing levels of AST, ALT, and LDH were suggested to be a result of model-specific liver cell injury due to ischemic damage and hemolysis after reperfusion injury, an effect, which has to be taken into consideration in all *ex vivo* perfused organ models (37).

Altogether, the different models of isolated perfused livers proved to be very complex in keeping organ function within physiological ranges, and their functional integrity was never maintained over a prolonged period. Furthermore, the establishment of these models is very expensive and ethical concerns about animal welfare prevent a more widespread use. However, future studies using organs from abattoirs may resolve ethical and economic problems. Also, the integration of powerful morphological and molecular biological methods such as immunohistochemistry (52, 69), RT-PCR (51), northern blotting (50), mRNA *in situ* hybridization (40, 49), or uptake studies (48) could significantly improve the impact of perfused organs.

#### Precision Cut Liver Slices

In view of the limitations of cell culture models with missing cell-to-cell interactions and the complexity of isolated perfused organs, new methods using liver slices were established. Dating back to 1923, liver slices were first prepared by Otto Warburg (35). The liver-slice models using precision-cut slices that were established in past years (43, 75) retain tissue organization and cell-to-cell matrix interactions such as perfused organs. However, bile flow and functional parameters such as portal flow cannot be analyzed. Due to the development of new tissue-slicer models, the main methodological problems of the liver slices that are represented by the poor




FIGURE 1.—In vitro liver toxicology models for drug discovery and development process.

diffusion of oxygen and nutrients have been improved. Now, slices in dimensions of less than 250- $\mu$ m thickness can be prepared with minimal tissue trauma (89). Recent studies demonstrated that the system can be used for periods of 2 to 3 days as a valid model to study hepatotoxicity and even human tissues can be used after surgical or needle biopsy removal (103).

Liver-slice models have been used in investigational pathology to assess a number of hepatotoxic effects and a variety of substances have been studied such as halogenated hydrocarbons (41), paracetamol (70), aflatoxin B1 (102), endotoxin (80), paraquat (97), cocaine (15), or metals such as zinc (107). Although the main advantages are represented by the preservation of lobular structures in contrast to cell cultures and the possible application of biochemical and molecular biological methods in contrast to organ perfusions, the main disadvantages are based on the short viability and the missing bile collection.

#### CONCLUSIONS

Over the last decades increasing costs of research coupled with animal welfare concerns have led to the development of new powerful *in vitro* models for the assessment of drug-induced hepatotoxicity. These models can also be used for the field of investigational pathology of environmental toxins. The 3 main approaches are represented by liver cell culture models, precision-cut liver slices, and *ex vivo* isolated and perfused organs. Each of these models has significant advantages with respect to specific scientific questions. Although the advantage of whole organ perfusions is based on the assessment of physiologic parameters such as bile production and morphologic parameters such as tissue histology, cell culture models can be efficiently used to assess cellular metabolism, cytotoxicity, and genotoxicity and lead to a reduction of laboratory animal use. The major future challenges will be to further improve the viability of each method, to establish a useful link between them (Figure 1) and to integrate new promising techniques such as laser-assisted cell harvesting (39).

#### ACKNOWLEDGMENTS

This study was supported by a grant of the BMBF (0311021). We thank M. Meissler, S. Nagel, C. Fehrenberg, and V. Unger for helpful discussions and W. Essig for excellent technical assistance.

#### REFERENCES

1. Abouna GM (1971). Extracorporeal liver perfusion for hepatic coma. *Lancet* 1: 1185.
2. Abouna GM, Ashcroft T, Hull C, Hodson A, Kirkley J, Walder DN (1969). The assessment of function of the isolated perfused porcine liver. *Br J Surg* 56: 289–295.

3. Abouna GM, Boehmig HG, Serrou B, Amemiya H, Martineau G (1970). Long-term hepatic support by intermittent multi-species liver perfusions. *Lancet* 2: 391–396.
4. Acosta D, Sorensen EM, Anuforo DC, Mitchell DB, Ramos K, Santone KS, Smith MA (1985). An in vitro approach to the study of target organ toxicity of drugs and chemicals. *In Vitro Cell Dev Biol* 21: 495–504.
5. Ambs S, Neumann HG (1996). Acute and chronic toxicity of aromatic amines studied in the isolated perfused rat liver. *Toxicol Appl Pharmacol* 139: 186–194.
6. Bacon JA, Cramer CT, Petrella DK, Sun EL, Ulrich RG (1996). Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. *Toxicology* 108: 9–16.
7. Bacon JA, Ulrich RG, Davis JP, Thomas EM, Johnson SS, Conder GA, Sangster NC, Rothwell JT, McCracken RO, Lee BH, Clothier MF, Geary TG, Thompson DP (1998). Comparative in vitro effects of closantel and selected beta-ketoamide anthelmintics on a gastrointestinal nematode and vertebrate liver cells. *J Vet Pharmacol Ther* 21: 190–198.
8. Bars RG, Bell DR, Elcombe CR, Oinonen T, Jalava T, Lindros KO (1992). Zone-specific inducibility of cytochrome P450 2B1/2 is retained in isolated perivenous hepatocytes. *Biochem J* 282: 635–638.
9. Bell DR, Bars RG, Elcombe CR (1992). Differential tissue-specific expression and induction of cytochrome P450 IVA1 and acyl-CoA oxidase. *Eur J Biochem* 206: 979–986.
10. Bell R, Shiel AG, Dolan P, Mears DC, Woodman K (1993). The evaluation of the isolated perfused liver as a model for the assessment of liver preservation. *Aust N Z J Surg* 63: 44–52.
11. Bereznowski Z (1997). Methacrylate uptake by isolated hepatocytes and perfused rat liver. *Int J Biochem Cell Biol* 29: 675–679.
12. Berry MN, Friend DS (1969). High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural study. *J Cell Biol* 43: 506–520.
13. Berry MN, Grivell AR, Grivell MB, Phillips JW (1997). Isolated hepatocytes—past, present and future. *Cell Biol Toxicol* 13: 223–233.
14. Blaauboer BJ, van Holsteijn CW, Bleumink R, Mennes WC, van Pelt FN, Yap SH, van Pelt JF, van Iersel AA, Timmerman A, Schmid BP (1990). The effect of becloric acid and clofibrilic acid on peroxisomal beta-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. *Biochem Pharmacol* 40: 521–528.
15. Boelsterli UA, Goldlin C (1991). Biomechanisms of cocaine-induced hepatocyte injury mediated by the formation of reactive metabolites. *Arch Toxicol* 65: 351–360.
16. Bouchard G, Yousef IM, Barriault C, Tuchweber B (2000). Role of glutathione and oxidative stress in phalloidin-induced cholestasis. *J Hepatol* 32: 550–560.
17. Bruck R, Frenkel D, Shirin H, Aeed H, Matas Z, Papa M, Zaidel L, Avni Y, Oren R, Halpern Z (1999). Hypothyroidism protects rat liver from acetaminophen hepatotoxicity. *Dig Dis Sci* 44: 1228–1235.
18. Bruck R, Prigozin H, Krepel Z, Rotenberg P, Shechter Y, Bar-Meir S (1991). Vanadate inhibits glucose output from isolated perfused rat liver. *Hepatology* 14: 540–544.
19. Burgmann H, Reckendorfer H, Sperlich M, Tuchy GL, Spieckermann PG, Weindlmayr-Gottel M, Schwarz S (1994). Influence of incubated atracurium on rat liver function. *Br J Anaesth* 72: 324–327.
20. Butterworth BE, Bermudez E, Smith-Oliver T, Earle L, Cattley R, Martin J, Popp JA, Strom S, Jirtle R, Michalopoulos G (1984). Lack of genotoxic activity of di(2-ethylhexyl)phthalate (DEHP) in rat and human hepatocytes. *Carcinogenesis* 5: 1329–1335.
21. Butterworth BE, Smith-Oliver T, Earle L, Loury DJ, White RD, Doolittle DJ, Working PK, Cattley RC, Jirtle R, Michalopoulos G, et al (1989). Use of primary cultures of human hepatocytes in toxicology studies. *Cancer Res* 49: 1075–1084.
22. Chari RS, Collins BH, Magee JC, DiMaio JM, Kirk AD, Harland RC, McCann RL, Platt JL, Meyers WC (1994). Treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. *N Engl J Med* 331: 234–237.
23. Chesne C, Guyomard C, Fautrel A, Poullain MG, Fremond B, De Jong H, Guillouzo A (1993). Viability and function in primary culture of adult hepatocytes from various animal species and human beings after cryopreservation. *Hepatology* 18: 406–414.
24. Conway JG, Popp JA, Ji S, Thurman RG (1983). Effect of size on portal circulation of hepatic nodules from carcinogen-treated rats. *Cancer Res* 43: 3374–3378.
25. Conway JG, Popp JA, Thurman RG (1985a). Microcirculation in periportal and pericentral regions of lobule in perfused rat liver. *Am J Physiol* 249: G449–456.
26. Conway JG, Popp JA, Thurman RG (1985b). Microcirculation of hepatic nodules from diethylnitrosamine-treated rats. *Cancer Res* 45: 3620–3625.
27. Cox JW, Dring LG, Ginsberg LC, Larson PG, Constable DA, Ulrich RG (1990). Distribution and disposition of trospectomycin sulfate in the in vivo rat, perfused rat liver, and cultured rat hepatocytes. *Drug Metab Dispos* 18: 726–731.
28. Cramer CT, Cooke S, Ginsberg LC, Kletzien RF, Stapleton SR, Ulrich RG (1995). Upregulation of glucose-6-phosphate dehydrogenase in response to hepatocellular oxidative stress: Studies with diquat. *J Biochem Toxicol* 10: 293–298.
29. de Sousa G, Nicolas F, Placidi M, Rahmani R, Benicourt M, Vannier B, Lorenzon G, Mertens K, Coecke S, Callaerts A, Rogiers V, Khan S, Roberts P, Skett P, Fautrel A, Chesne C, Guillouzo A (1999). A multi-laboratory evaluation of cryopreserved monkey hepatocyte functions for use in pharmacotoxicology. *Chem Biol Interact* 121: 77–97.
30. Deters M, Strubelt O, Younes M (1997). Reevaluation of cyclosporine induced hepatotoxicity in the isolated perfused rat liver. *Toxicology* 123: 197–206.
31. Drapanas T, Zemel R, Vang JO (1966). Hemodynamics of the isolated perfused pig liver: Metabolism according to routes of perfusion and rates of flow. *Ann Surg* 164: 522–537.
32. Dunn JC, Yarmush ML, Koebe HG, Tompkins RG (1989). Hepatocyte function and extracellular matrix geometry: Long-term culture in a sandwich configuration. *FASEB J* 3: 174–177.
33. Edwards MJ, Keller BJ, Kauffman FC, Thurman RG (1993). The involvement of Kupffer cells in carbon tetrachloride toxicity. *Toxicol Appl Pharmacol* 119: 275–279.
34. Eiseman B, Liem DS, Raffucci F (1965). Heterologous liver perfusion in treatment of hepatic failure. *Ann Surg* 162: 329–345.
35. Ekins S (1996). Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. *Drug Metab Rev* 28: 591–623.
36. El-Bahay C, Gerber E, Horbach M, Tran-Thi QH, Rohrdanz E, Kahl R (1999). Influence of tumor necrosis factor-alpha and silibin on the cytotoxic action of alpha-amanitin in rat hepatocyte culture. *Toxicol Appl Pharmacol* 158: 253–260.
37. Elmslie RG, Rao MM, Howe LA, Hall P (1971). Functional deficits in the isolated perfused pig liver. *Surg Gynecol Obstet* 133: 89–92.
38. Fardel O, Morel F, Guillouzo A (1993). P-glycoprotein expression in human, mouse, hamster and rat hepatocytes in primary culture. *Carcinogenesis* 14: 781–783.
39. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, Bohle RM (1998). Real-time quantitative RT-PCR after laser-assisted cell picking. *Nat Med* 4: 1329–1333.
40. Fischer TC, Hartmann P, Loser C, Springer J, Peiser C, Dinh QT, Fischer A, Groneberg DA (2001). Abundant expression of vasoactive intestinal polypeptide receptor VPAC2 mRNA in human skin. *J Invest Dermatol* 117: 754–756.
41. Fraga CG, Leibovitz BE, Tappel AL (1987). Halogenated compounds as inducers of lipid peroxidation in tissue slices. *Free Radic Biol Med* 3: 119–123.
42. Frodin L (1975). Renal transplantation in the rat. II. In vitro perfusion of rat kidneys before transplantation. *Scand J Clin Lab Invest* 35: 455–462.
43. Gandolfi AJ, Wijeweera J, Brendel K (1996). Use of precision-cut liver slices as an in vitro tool for evaluating liver function. *Toxicol Pathol* 24: 58–61.
44. Gebhardt R (1992). Metabolic zonation of the liver: Regulation and implications for liver function. *Pharmacol Ther* 53: 275–354.
45. Gebhardt R, Gaunitz F (1997). Cell-cell interactions in the regulation of the expression of hepatic enzymes. *Cell Biol Toxicol* 13: 263–273.

46. Gootz TD (1990). Discovery and development of new antimicrobial agents. *Clin Microbiol Rev* 3: 13–31.
47. Gordon EM, Douglas MC, Jablonski P, Owen JA, Sali A, Watts JM (1972). Gastrointestinal hormones and bile-secretion studies in the isolated perfused pig liver. *Surgery* 72: 708–721.
48. Groneberg DA, Doring F, Eynott PR, Fischer A, Daniel H (2001). Intestinal peptide transport: Ex vivo uptake studies and localization of peptide carrier PEPT1. *Am J Physiol Gastrointest Liver Physiol* 281: G697–704.
49. Groneberg DA, Doring F, Nickolaus M, Daniel H, Fischer A (2001). Expression of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root ganglia. *Neurosci Lett* 304: 181–184.
50. Groneberg DA, Hartmann P, Dinh QT, Fischer A (2001). Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. *Lab Invest* 81: 749–755.
51. Groneberg DA, Nickolaus M, Springer J, Doring F, Daniel H, Fischer A (2001). Localization of the peptide transporter PEPT2 in the lung: Implications for pulmonary oligopeptide uptake. *Am J Pathol* 158: 707–714.
52. Groneberg DA, Wiegand S, Dinh QT, Peiser C, Springer J, Fischer A (2001). Expression of immediate early genes in sensory ganglia. *Neurochem Res* 26: 1113–1117.
53. Guillouzo A, Morel F, Fardel O, Meunier B (1993). Use of human hepatocyte cultures for drug metabolism studies. *Toxicology* 82: 209–219.
54. Guyomard C, Chesne C, Meunier B, Fautrel A, Clerc C, Morel F, Rissel M, Campion JP, Guillouzo A (1990). Primary culture of adult rat hepatocytes after 48-hour preservation of the liver with cold UW solution. *Hepatology* 12: 1329–1336.
55. Ham JM, Pirola RC, Elmslie RG (1969). Function of the isolated perfused pig liver. *Surg Gynecol Obstet* 129: 470–474.
56. Hems R, Ross BD, Berry MN, Krebs HA (1966). Gluconeogenesis in the perfused rat liver. *Biochem J* 101: 284–292.
57. Hillesheim W, Jaeschke H, Neumann HG (1995). Cytotoxicity of aromatic amines in rat liver and oxidative stress. *Chem Biol Interact* 98: 85–95.
58. Hobbs KE, Hunt AC, Palmer DB, Badrick FE, Morris AM, Mitra SK, Peacock JH, Immelman EJ, Riddell AG (1968a). Hypothermic perfusion as a method of short-term porcine liver storage. *Br J Surg* 55: 862.
59. Hobbs KE, Hunt AC, Palmer DB, Badrick FE, Morris AM, Mitra SK, Peacock JH, Immelman EJ, Riddell AG (1968b). Hypothermic low flow liver perfusion as a means of porcine hepatic storage for six hours. *Br J Surg* 55: 696–703.
60. Horbach M, Gerber E, Kahl R (1997). Influence of acetaminophen treatment and hydrogen peroxide treatment on the release of a CINC-related protein and TNF-alpha from rat hepatocyte cultures. *Toxicology* 121: 117–126.
61. Howard RB, Christensen AK, Gibbs FA, Pesch LA (1967). The enzymatic preparation of isolated intact parenchymal cells from rat liver. *J Cell Biol* 35: 675–684.
62. Howard RB, Pesch LA (1968). Respiratory activity of intact, isolated parenchymal cells from rat liver. *J Biol Chem* 243: 3105–3109.
63. Ikeda T, Yanaga K, Lebeau G, Higashi H, Kakizoe S, Starzl TE (1990). Hemodynamic and biochemical changes during normothermic and hypothermic sanguinous perfusion of the porcine hepatic graft. *Transplantation* 50: 564–567.
64. Jablonski P, Douglas MC, Gordon E, Owen JA, Watts JM (1971). Studies on the isolated perfused pig liver. *Br J Surg* 58: 129–137.
65. Koebe HG, Dunn JC, Toner M, Sterling LM, Hubel A, Cravalho EG, Yarmush ML, Tompkins RG (1990). A new approach to the cryopreservation of hepatocytes in a sandwich culture configuration. *Cryobiology* 27: 576–584.
66. Koop DR, Chernosky A, Brass EP (1991). Identification and induction of cytochrome P450 2E1 in rat Kupffer cells. *J Pharmacol Exp Ther* 258: 1072–1076.
67. Lerche C, Fautrel A, Shaw PM, Glaize D, Ballet F, Guillouzo A, Corcos L (1997). Regulation of the major detoxication functions by phenobarbital and 3-methylcholanthrene in co-cultures of rat hepatocytes and liver epithelial cells. *Eur J Biochem* 244: 98–106.
68. Lerche C, Le Jossic C, Fautrel A, de Waziers I, Ballet F, Guillouzo A, Corcos L (1996). Rat liver epithelial cells express functional cytochrome P450 2E1. *Carcinogenesis* 17: 1101–1106.
69. Lim S, Groneberg D, Fischer A, Oates T, Caramori G, Mattos W, Adcock I, Barnes PJ, Chung KF (2000). Expression of heme oxygenase isoenzymes 1 and 2 in normal and asthmatic airways: Effect of inhaled corticosteroids. *Am J Respir Crit Care Med* 162: 1912–1918.
70. Lohmann J, Lessing U, Schriewer H, Clemens M, Gerlach U (1984). The influence of paracetamol on the hepatic biosynthesis of lecithin. *Arch Toxicol Suppl* 7: 236–239.
71. Masumi S, Moriyama M, Kannan Y, Ohta M, Koshitani O, Sawamoto O, Sugano T (1999). Changes in hepatic nitrogen metabolism in isolated perfused liver during the development of thioacetamide-induced cirrhosis in rats. *Toxicology* 135: 21–31.
72. Meren H, Varin F, Ruwart M, Thurman RG (1986). Effect of 16,16-dimethyl prostaglandin E2 on oxygen uptake and microcirculation in the perfused rat liver. *Hepatology* 6: 917–921.
73. Nastevska C, Gerber E, Horbach M, Rohrdanz E, Kahl R (1999). Impairment of TNF-alpha expression and secretion in primary rat liver cell cultures by acetaminophen treatment. *Toxicology* 133: 85–92.
74. Palmen NG, Evelo CT, Borm PJ, Henderson PT (1993). Toxicokinetics of dimethylacetamide (DMAc) in rat isolated perfused liver. *Hum Exp Toxicol* 12: 127–133.
75. Parrish AR, Gandolfi AJ, Brendel K (1995). Precision-cut tissue slices: applications in pharmacology and toxicology. *Life Sci* 57: 1887–1901.
76. Piscaglia F, Knittel T, Kobold D, Barnikol-Watanabe S, Di Rocco P, Ramadori G (1999). Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. *Biochem Pharmacol* 58: 157–165.
77. Poullain MG, Fautrel A, Guyomard C, Chesne C, Grislain L, Guillouzo A (1992). Viability and primary culture of rat hepatocytes after hypothermic preservation: The superiority of the Leibovitz medium over the University of Wisconsin solution for cold storage. *Hepatology* 15: 97–106.
78. Ratanasavanh D, Baffet G, Latinier MF, Rissel M, Guillouzo A (1988). Use of hepatocyte co-cultures in the assessment of drug toxicity from chronic exposure. *Xenobiotica* 18: 765–771.
79. Raymond SL, Pert JH, Dodds WJ (1975). Evaluation of platelet cryopreservation techniques by isolated kidney perfusion. *Transfusion* 15: 219–225.
80. Richards PS, Saba TM (1985). Effect of endotoxin on fibronectin and Kupffer cell activity. *Hepatology* 5: 32–37.
81. Schon MR, Puhl G, Frank J, Neuhaus P (1993). Hemodialysis improves results of pig liver perfusion after warm ischemic injury. *Transplant Proc* 25: 3239–3243.
82. Schrenk D, Eisenmann-Tappe I, Gebhardt R, Mayer D, el Mouelhi M, Rohrdanz E, Munzel P, Bock KW (1991). Drug metabolizing enzyme activities in rat liver epithelial cell lines, hepatocytes and bile duct cells. *Biochem Pharmacol* 41: 1751–1757.
83. Schuetz EG, Schuetz JD, May B, Guzelian PS (1990). Regulation of cytochrome P-450b/e and P-450p gene expression by growth hormone in adult rat hepatocytes cultured on a reconstituted basement membrane. *J Biol Chem* 265: 1188–1192.
84. Seglen PO (1972). Preparation of rat liver cells. I. Effect of Ca<sup>2+</sup> on enzymatic dispersion of isolated, perfused liver. *Exp Cell Res* 74: 450–454.
85. Seglen PO (1973). Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. *Exp Cell Res* 82: 391–398.
86. Shen W, Hoener B (1996). Mitigation of nitrofurantoin-induced toxicity in the perfused rat liver. *Hum Exp Toxicol* 15: 428–434.
87. Sidhu JS, Farin FM, Omiecinski CJ (1993). Influence of extracellular matrix overlay on phenobarbital-mediated induction of CYP2B1, 2B2, and 3A1 genes in primary adult rat hepatocyte culture. *Arch Biochem Biophys* 301: 103–113.
88. Sinclair PR, Schuetz EG, Bement WJ, Haugen SA, Sinclair JF, May BK, Li D, Guzelian PS (1990). Role of heme in phenobarbital induction of cytochromes P450 and 5-aminolevulinat e synthase in cultured rat hepatocytes maintained on an extracellular matrix. *Arch Biochem Biophys* 282: 386–392.

89. Smith PF, Krack G, McKee RL, Johnson DG, Gandolfi AJ, Hruby VJ, Krumdieck CL, Brendel K (1986). Maintenance of adult rat liver slices in dynamic organ culture. *In Vitro Cell Dev Biol* 22: 706-712.
90. Steele VE, Boone CW, Lubet RA, Crowell JA, Holmes CA, Sigman CC, Kelloff GJ (1998). Preclinical drug development paradigms for chemopreventives. *Hematol Oncol Clin North Am* 12: 943-961, v-vi.
91. Strubelt O, Deters M, Pentz R, Siegers CP, Younes M (1999). The toxic and metabolic effects of 23 aliphatic alcohols in the isolated perfused rat liver. *Toxicol Sci* 49: 133-142.
92. Strubelt O, Kremer J, Tilse A, Keogh J, Pentz R, Younes M (1996). Comparative studies on the toxicity of mercury, cadmium, and copper toward the isolated perfused rat liver. *J Toxicol Environ Health* 47: 267-283.
93. Sun EL, Feenstra KL, Bell FP, Sanders PE, Slatter JG, Ulrich RG (1996). Biotransformation of lifibrol (U-83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture. *Drug Metab Dispos* 24: 221-231.
94. Teo S, Vore M (1991). Mirex inhibits bile acid secretory function in vivo and in the isolated perfused rat liver. *Toxicol Appl Pharmacol* 109: 161-170.
95. Terblanche J, Hickman R (1991). Animal models of fulminant hepatic failure. *Dig Dis Sci* 36: 770-774.
96. Timbrell JA (1983). Drug hepatotoxicity. *Br J Clin Pharmacol* 15: 3-14.
97. Togashi H, Shinzawa H, Wakabayashi H, Nakamura T, Yong H, Yamada N, Ukai K, Okuyama Y, Takahashi T, Ishikawa M (1991). Superoxide is involved in the pathogenesis of paraquat-induced injury in cultured rat liver slices. *Hepatology* 14: 707-714.
98. Ulrich RG, Aspar DG, Cramer CT, Kletzien RF, Ginsberg LC (1990). Isolation and culture of hepatocytes from the cynomolgus monkey (*Macaca fascicularis*). *In Vitro Cell Dev Biol* 26: 815-823.
99. Ulrich RG, Bacon JA, Cramer CT, Peng GW, Petrella DK, Stryd RP, Sun EL (1995). Cultured hepatocytes as investigational models for hepatic toxicity: Practical applications in drug discovery and development. *Toxicol Lett* 82-83: 107-115.
100. Ulrich RG, Bacon JA, Cramer CT, Petrella DK, Sun EL, Meglasson MD, Holmuhamedov E (1998). Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite. *Toxicology* 131: 33-47.
101. Ulrich RG, Cramer CT, Adams LA, Kletzien RF (1998). Activation and glucagon regulation of mitogen-activated protein kinases (MAPK) by insulin and epidermal growth factor in cultured rat and human hepatocytes. *Cell Biochem Funct* 16: 77-85.
102. Uwaifo AO (1984). Inhibition of oxygen uptake in liver slices of three mammalian species (rat, rabbit, guinea-pig) by aflatoxin B1 (AFB1). *Toxicology* 31: 33-39.
103. Vickers AE (1994). Use of human organ slices to evaluate the biotransformation and drug-induced side-effects of pharmaceuticals. *Cell Biol Toxicol* 10: 407-414.
104. Videla LA, Troncoso P, Arisi AC, Junqueira VB (1997). Dose-dependent effects of acute lindane treatment on Kupffer cell function assessed in the isolated perfused rat liver. *Xenobiotica* 27: 747-757.
105. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG (2001). Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. *Toxicol Lett* 120: 359-368.
106. Wilhelm M, Jaeger DE, Schull-Cablitz H, Hafner D, Idel H (1996). Hepatic clearance and retention of aluminium: Studies in the isolated perfused rat liver. *Toxicol Lett* 89: 257-263.
107. Wormser U, Ben-Zakine S (1989). Protective effect of zinc against hepatotoxic agents in the rat liver slice system: Role of metallothionein. *Arch Toxicol Suppl* 13: 316-318.